Earnings call transcript: Huron Consulting Group Q1 2026 beats expectations

Huron Consulting Group delivered a solid Q1 2026 beat, with EPS of $1.73 versus $1.61 expected and revenue of $443.7 million above the $438.2 million consensus. Revenue rose 12.1% year over year, led by record Healthcare RVR of $225.2 million, while the company affirmed full-year guidance and highlighted strong bookings and pipeline growth. Shares ticked up 0.08% after hours, and management reiterated AI-driven growth, ongoing buybacks, and continued tuck-in M&A, though the company noted some analyst downward revisions.

Analysis

HURN is quietly turning into a cleaner compounding story than the headline print suggests. The key second-order effect is not just top-line acceleration, but the mix shift toward longer-duration, larger engagements in Healthcare that supports utilization and makes the revenue base stickier; that matters because consulting multiples re-rate when backlog quality improves faster than reported growth. The combination of record backlog coverage, mid-teens margin trajectory, and an aggressive buyback cadence creates a mechanical EPS tailwind even if organic growth normalizes.

The market is probably underestimating how much the centralized support reorganization and AI/digital investment can lift margins over the next 2-4 quarters. Near term, the biggest risk is cash conversion rather than demand: DSOs tied to performance-fee projects and seasonal bonus outflows can keep reported leverage elevated, which may slow buybacks exactly when the stock is cheapest. That creates a timing mismatch where the equity can rerate on earnings quality while the balance sheet looks temporarily worse.

The contrarian view is that consensus may be overpaying for the AI narrative and underpricing client-budget friction. HURN does have real distribution into regulated industries, but if digital work remains choppy while acquisitions get harder to source, growth could revert toward a high-quality low-double-digit services compounder rather than an AI multiple story. In that case, the stock should be bought on execution dips, not chased into strength, because the valuation upside depends on sustained margin expansion and continued capital return discipline rather than a single quarter of beat-and-raise optics.

Key Decisions for Investors

• Long HURN for 3-6 months on any post-earnings consolidation; target a re-rating toward the lower end of analyst price bands if backlog and margin commentary hold, with downside capped by active repurchases.
• Pair trade: long HURN / short lower-quality consulting services names with weaker balance sheets and less exposure to regulated healthcare demand; express over 1-2 quarters as capital returns and backlog quality separate winners from cyclical consultants.
• Use HURN calls rather than stock if entering fresh: buy 3-4 month call spreads to capture rerating from margin expansion while limiting risk from DSO/leverage volatility.
• Fade the AI premium if the stock rallies sharply above fundamental support; trim on any sign that digital growth or M&A cadence slows, since the near-term driver is operating leverage, not optionality.
• Monitor leverage and cash collection closely into the back half of 2026; if DSOs normalize and buybacks continue, add to the long, but if cash conversion stays weak, reduce exposure before the market focuses on balance-sheet optics.